Browse EX-10 agreements

COMMERCIAL LEASE 1 Page PARTIES Bradford Street, LLC, LESSOR, which expression shall include heirs, successors, and assigns where the context so admits, does hereby lease to Aldeyra Therapeutics, Inc., 131 Hartwell Ave, Suite 320, Lexington, MA 02421, LESSEE, which expression shall include successors, executors, administrators, and assigns where the context so admits, and LESSEE hereby leases the following described leased premises (the “Premises”) at the Bradford Mill in Concord, MA. PREMISES Approximately 4,067 rentable square feet located on the first floor of 23 Bradford Street, Concord, Massachusetts 01742, commonly known as Suite 23-1 Front. TERM The term of this lease shall be for three (3) years commencing on September 1, 2026 and ending on September 30, 2029. RENT Rent of $12,201 is due on the first day of every month: Lease Year Annual Rent Rent/Month 9/1/2026 – 9/30/2026 Abated $0 10/1/2026 – 10/31/2027 $146,412 $12,201 11/1/2027 – 10/31/2028 $150,480 $12,540 11/1/2028 – 9/30/2029 $154,548 $12,879 Provided LESSEE is not in default beyond applicable notice and cure periods

…

** **

REGISTRATION RIGHTS AGREEMENT

This Registration Rights Agreement (this “Agreement”) is entered into effective as of July 28, 2026 (the “Execution Date”), by and between LogicMark, Inc., a Nevada corporation (the “Company”), and White Lion Capital LLC, a Nevada limited liability company (the “Investor”).

** **

RECITALS

** **

WHEREAS, in connection with the Securities Purchase Agreement, dated as of the date hereof, by and between the Company and the Investor (the “Purchase Agreement”), the Company shall issue and sell to the Investor, and the Investor shall purchase from the Company, 250,000 shares of Series J Preferred Stock, $0.0001 par value per share (the “Preferred Shares”) at a purchase price of $1.00 per share (the “Purchase Price”). Such Preferred Shares shall be convertible into the Company’s Common Stock, par value $0.0001 per share (the “Common Shares”), such Common Shares (the “Conversion Shares”); and

** **

…

SECURITIES PURCHASE AGREEMENT

THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), is made as of July 28, 2026 (the “Effective Date”), by and among LogicMark, Inc. a Nevada corporation (the “Company”), and White Lion Capital LLC, a Nevada limited liability company (the “Purchaser”).

The parties hereby agree as follows:

1. Purchase and Sale of Preferred Stock.

1.1 Sale and Issuance of Preferred Stock.

(a) The Company shall adopt and file with the Secretary of State of the State of Nevada on or before the Closing (as defined below) the certificate of designation (the “Certificate of Designation”) in the form of Exhibit A attached to this Agreement.

…

EXECUTIVE EMPLOYMENT AGREEMENT

** **

This Executive Employment Agreement (the “Agreement”) is effective as of July 27, 2026 (“Effective Date”), between Mark Archer (the “Executive”) and LogicMark, Inc., a Nevada corporation (the “Company”). The Company and Executive will collectively be referred to as the “Parties.”

RECITALS

| | | |

…

EXECUTIVE EMPLOYMENT AGREEMENT

** **

This Executive Employment Agreement (the “Agreement”) executed on July 27, 2026 is amended and restated effective as of May 10, 2026 (“Effective Date”), between Chia-Lin Simmons (the “Executive”) and LogicMark, Inc., a Nevada corporation (the “Company”). The Company and Executive will collectively be referred to as the “Parties.”

RECITALS

| | | |

…

** **

VOTING AGREEMENT

This Voting Agreement (this “Voting Agreement”) is being delivered to you in connection with an understanding by and between LogicMark, Inc., a Nevada corporation (the “Company”), and the person or persons named on the signature pages attached hereto.

Reference is hereby made to the Securities Purchase Agreement (the “SPA”) dated July 28, 2026, by and between you and the Company relating to the purchase of 250,000 shares of Series J Convertible Preferred Stock of the Company, $0.0001 par value per share (the “Preferred Stock”) by you (the “Holder”).

…

**ORIC PHARMACEUTICALS, INC. **

**AMENDED AND RESTATED **

**2022 INDUCEMENT EQUITY INCENTIVE PLAN **

1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permits the grant of Nonstatutory Stock Options, Restricted Stock, Restricted Stock Units, Stock Appreciation Rights, Performance Units and Performance Shares. Each Award under the Plan is intended to qualify as an employment inducement grant under Nasdaq Listing Rule 5635(c)(4) and the official regulations thereunder (together, the “Inducement Listing Rule”) or to qualify under the exception relating to plans or arrangements relating to an acquisition or merger under Nasdaq Listing Rule 5635(c)(3) and the official guidance thereunder.

2. Definitions. As used herein, the following definitions will apply:

…

[LOGO]

Exhibit 10.1

CERTAIN INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT IN ACCORDANCE WITH ITEM 601(A)(6) OF REGULATION S-K DUE TO PERSONAL PRIVACY CONCERNS. INFORMATION THAT HAS BEEN SO REDACTED FROM THIS EXHIBIT HAS BEEN MARKED WITH “[***]” TO INDICATE THE OMISSION.

July 25, 2026

Brijesh Krishnaswamy    

[***]

Re: At-Will Employment Offer

Dear Brijesh,

Beyond Meat, Inc., a Delaware corporation (the “Company”), is pleased to offer you employment with the Company on the terms described below.

…

EMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT (this “Agreement”) dated as of July 29, 2026 (the “Effective Date”), is made by and among Coastal Financial Corporation (the “Company”), Everett, Washington, and Christopher D. Adams (the “Executive”).

WHEREAS, the Company desires to hire the Executive as Executive Chair of the Company, and the Executive desires to accept an offer of employment to serve as Executive Chair of the Company; and

WHEREAS, the parties desire to enter into an employment relationship on the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the mutual covenants herein contained, the receipt and sufficiency of which are acknowledged, the parties hereby agree as follows.

1.POSITION.

During the period of his employment hereunder, the Executive agrees to serve as Executive Chair of the Board of Directors of the Company (the “Board”).

2.TERM AND DUTIES.

…

CONSULTING AGREEMENT

This Consulting Agreement (this “Agreement”) is made as of July 24, 2026 (the “Effective Date”), by and between Dr. Jacob Frenkel, PhD, MA (“Consultant”) and Brainstorm Cell Therapeutics Inc. (the “Company”). Consultant and the Company are each a “Party” and together the “Parties.”

1.             Consulting Terms.

(a)**       **Consulting Period. The Company engages Consultant, and Consultant agrees, to perform services upon the terms set forth in this Agreement, beginning on the Effective Date and ending on the date that is 9 months after the Effective Date (the “End Date”), unless terminated earlier pursuant to this Agreement (the “Consulting Period”).

…

BRAINSTORM CELL THERAPEUTIC INC.
2014 STOCK INCENTIVE PLAN
STOCK OPTION GRANT NOTICE

Brainstorm Cell Therapeutics Inc., a Delaware corporation, (the “Company”), pursuant to its 2014 Stock Incentive Plan, as may be amended from time to time (the “Plan”), hereby grants to the individual listed below (the “Participant”), an option to purchase the number of shares of the Company’s Common Stock (the “Shares”), set forth below (the “Option”). This Option is subject to all the terms and conditions set forth herein, as well as in the Plan and the Agreement attached hereto as Exhibit A (the “Agreement”), each of which are incorporated herein by reference. Capitalized terms not specifically defined in this Stock Option Grant Notice (the “Grant Notice”) and the Agreement but defined in the Plan will have the same definitions as in the Plan.

…

July 24, 2026

Peter J. Pitts

Dear Peter:

On behalf of Brainstorm Cell Therapeutics Inc. (the “Company”), I am pleased to provide you with this letter agreement (this “Agreement”) setting forth the terms and conditions of your employment as Executive Chairman and Chief Strategic Regulatory Officer (“Chairman”) of the Company, effective as of July 24, 2026 (the “Effective Date”).

1.            Term. The Company will employ you as Chairman, upon the terms and subject to the conditions set forth in this Agreement, beginning on the Effective Date and ending when your employment terminates pursuant to paragraph 9 (the “Term”).

…